PIERI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.743
EU - Europa 4.236
AS - Asia 556
AF - Africa 27
OC - Oceania 14
SA - Sud America 14
Totale 9.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.729
PL - Polonia 2.208
RU - Federazione Russa 825
IT - Italia 343
IE - Irlanda 265
SE - Svezia 263
SG - Singapore 164
CN - Cina 111
HK - Hong Kong 94
CH - Svizzera 73
FI - Finlandia 69
DE - Germania 68
IN - India 51
GB - Regno Unito 34
VN - Vietnam 34
FR - Francia 27
KR - Corea 24
TR - Turchia 24
JO - Giordania 20
AE - Emirati Arabi Uniti 19
UA - Ucraina 19
CA - Canada 14
AU - Australia 12
BE - Belgio 12
CI - Costa d'Avorio 12
AT - Austria 11
ES - Italia 10
BR - Brasile 6
EG - Egitto 5
CO - Colombia 4
JP - Giappone 4
PE - Perù 4
ZA - Sudafrica 4
BY - Bielorussia 2
IR - Iran 2
KE - Kenya 2
NL - Olanda 2
NZ - Nuova Zelanda 2
RO - Romania 2
SC - Seychelles 2
TW - Taiwan 2
AO - Angola 1
AZ - Azerbaigian 1
EE - Estonia 1
GE - Georgia 1
MU - Mauritius 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 9.590
Salva come PNG Salva come JPEG
Città #
Warsaw 2.208
Santa Clara 754
Fairfield 747
Ashburn 355
Woodbridge 329
Seattle 308
Chandler 279
Dublin 264
Houston 256
Wilmington 246
Cambridge 245
Ann Arbor 148
Singapore 129
Altamura 109
Lawrence 108
Princeton 81
Bern 72
Boston 65
Florence 61
Jacksonville 52
Beijing 44
Mumbai 43
Hong Kong 38
San Diego 37
Boardman 30
Buffalo 30
Dong Ket 30
Bremen 28
New York 26
Shanghai 25
Izmir 22
Moscow 22
Seoul 21
Medford 20
Abu Dhabi 19
Phoenix 16
Norwalk 15
Abidjan 12
Brussels 12
Kent 12
Vienna 11
Barcelona 10
Hillsboro 10
Sydney 10
Dearborn 9
Rome 9
London 8
Andover 7
Helsinki 6
Los Angeles 6
Parnaiba 6
Pune 6
Toronto 6
Yubileyny 6
Alexandria 4
Cagliari 4
Campi Bisenzio 4
Falls Church 4
Milan 4
Montreal 4
Munich 4
Redwood City 4
Romainville 4
West Jordan 4
Blaine 3
Bovalino 3
Getzville 3
Guangzhou 3
Laurel 3
Noicattaro 3
Padova 3
Paris 3
Pesaro 3
Quartu Sant'Elena 3
Athens 2
Bari 2
Bogotá 2
Brescia 2
Brest 2
Cantagallo 2
Cecina 2
Cincinnati 2
Costa Mesa 2
Farra di Soligo 2
Gomel 2
Huancayo 2
Johannesburg 2
Kharkov 2
Kilburn 2
La Mesa 2
Lima 2
Medellín 2
Nürnberg 2
Old Bridge 2
Perugia 2
Pisa 2
Prato 2
Prescot 2
Pretoria 2
Reading 2
Totale 7.550
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 329
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 281
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 277
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 268
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 267
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 263
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 260
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 248
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 243
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 243
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 239
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 237
Chronic myeloproliferative neoplasms: a collaborative approach. 234
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 228
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 225
Imaging studies in extramedullary hematopoiesis of the spleen 221
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms 220
MPN Score 179
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 172
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 154
Mutations and prognosis in primary myelofibrosis. 135
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 135
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 129
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 127
Treatment options for essential thrombocythemia and polycythemia vera 124
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 122
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 120
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 119
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 117
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 117
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 112
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 111
Risk of second cancers in chronic myeloproliferative neoplasms. 111
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 110
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 110
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 108
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 108
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 108
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 105
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. 104
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. 104
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 104
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 101
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 100
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 100
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 100
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 99
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 98
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 97
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 97
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 96
Rationale for combination therapies in myelofibrosis 94
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 93
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 92
Risk of second cancers in chronic myeloproliferative neoplasms 90
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. 87
Prognotic Impact of Mutations in Systemic Mastocytosis 85
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 81
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. 79
Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B 79
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution 77
Masked polycythemia vera (mPV): results of an international study. 76
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 76
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics. 75
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 74
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. 69
Policitemia Vera. per conoscerla meglio. 68
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 63
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 59
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience 58
Totale 9.691
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.663
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.663
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.445 0 0 0 0 238 235 223 247 197 122 155 28
2020/20211.083 103 114 42 154 66 96 55 89 101 121 73 69
2021/2022488 14 48 48 16 13 19 20 39 27 26 76 142
2022/20231.353 121 289 68 111 94 216 160 66 102 15 34 77
2023/2024519 16 46 76 22 46 72 17 110 10 31 46 27
2024/20252.036 90 319 210 478 939 0 0 0 0 0 0 0
Totale 9.691